Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Ovarian Neoplasms

Free Subscription 02.01.2012 3 Am J Obstet Gynecol 13 Ann Oncol 1 Cancer Chemother Pharmacol 1 Clin Cancer Res 6 Gynecol Oncol 2 J Clin Oncol 2 Oncol Rep

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Obstet Gynecol

1. HOLCOMB K , Vucetic Z, Miller MC, Knapp RC, et al
   Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women.
   Am J Obstet Gynecol. 2011;205:358.
   PubMed     Text format     Related articles    Abstract available
   
   
   
2. ROUSSET P , Chaillot PF, Bats AS, Le Frere Belda MA, et al
   A regressive Meigs syndrome after definitive adnexal torsion.
   Am J Obstet Gynecol. 2011;205:e4-5.
   PubMed     Text format     Related articles    Abstract available
   
   
   
3. NAOURA I , Didelot A, Walker F, Luton D, et al
   Anti-N-methyl-D-aspartate receptor encephalitis complicating ovarian teratomas: a case report.
   Am J Obstet Gynecol. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   

   
   Ann Oncol

4. BELL-MCGUINN K , Konner J, Tew W, Spriggs DR, et al
   New drugs for ovarian cancer.
   Ann Oncol. 2011;22 Suppl 8:viii77-viii82.
   PubMed     Text format     Related articles   
   
   
   
5. SESSA C
   Update on PARP1 inhibitors in ovarian cancer.
   Ann Oncol. 2011;22 Suppl 8:viii72-viii76.
   PubMed     Text format     Related articles    Abstract available
   
   
   
6. MARKMAN M
   The use of bevacizumab in the management of ovarian cancer: an argument for single-agent rather than combination therapy.
   Ann Oncol. 2011;22 Suppl 8:viii69-viii71.
   PubMed     Text format     Related articles    Abstract available
   
   
   
7. BURGER RA
   Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer.
   Ann Oncol. 2011;22 Suppl 8:viii65-viii68.
   PubMed     Text format     Related articles    Abstract available
   
   
   
8. URBAN N
   Designing early detection programs for ovarian cancer.
   Ann Oncol. 2011;22 Suppl 8:viii6-viii18.
   PubMed     Text format     Related articles    Abstract available
   
   
   
9. BAST RC JR
   Molecular approaches to personalizing management of ovarian cancer.
   Ann Oncol. 2011;22 Suppl 8:viii5-viii15.
   PubMed     Text format     Related articles    Abstract available
   
   
   
10. EISENHAUER EA
    Optimal assessment of response in ovarian cancer.
    Ann Oncol. 2011;22 Suppl 8:viii49-viii51.
    PubMed     Text format     Related articles    Abstract available
    
    
    
11. RUSTIN GJ
    Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed.
    Ann Oncol. 2011;22 Suppl 8:viii45-viii48.
    PubMed     Text format     Related articles    Abstract available
    
    
    
12. PIGNATA S , Cannella L, Leopardo D, Bruni GS, et al
    Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up.
    Ann Oncol. 2011;22 Suppl 8:viii40-viii44.
    PubMed     Text format     Related articles    Abstract available
    
    
    
13. VAN DER BURG ME , Boere IA, Berns PM
    Dose-dense therapy is of benefit in primary treatment of ovarian cancer: contra.
    Ann Oncol. 2011;22 Suppl 8:viii33-viii39.
    PubMed     Text format     Related articles    Abstract available
    
    
    
14. KATSUMATA N
    Dose-dense therapy is of benefit in primary treatment of ovarian cancer? In favor.
    Ann Oncol. 2011;22 Suppl 8:viii29-viii32.
    PubMed     Text format     Related articles    Abstract available
    
    
    
15. KANG S , Park SY
    To predict or not to predict? The dilemma of predicting the risk of suboptimal cytoreduction in ovarian cancer.
    Ann Oncol. 2011;22 Suppl 8:viii23-viii28.
    PubMed     Text format     Related articles    Abstract available
    
    
    
16. HACKER NF
    Quality control in ovarian cancer surgery.
    Ann Oncol. 2011;22 Suppl 8:viii19-viii22.
    PubMed     Text format     Related articles    Abstract available
    
    
    

    
    Cancer Chemother Pharmacol

17. ZAMBONI WC , Combest AJ, DeLoia JA, Edwards RP, et al
    Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer.
    Cancer Chemother Pharmacol. 2011;68:1255-62.
    PubMed     Text format     Related articles    Abstract available
    
    
    

    
    Clin Cancer Res

18. MORENO-SMITH M , Lu C, Shahzad MM, Armaiz-Pena GN, et al
    Dopamine blocks stress mediated ovarian carcinoma growth.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles   
    
    
    

    
    Gynecol Oncol

19. XU JL , Commins J, Partridge E, Riley TL, et al
    Longitudinal evaluation of CA-125 velocity and prediction of ovarian cancer.
    Gynecol Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
20. ARMSTRONG DK , Visvanathan K
    The "luxury" of second malignancies.
    Gynecol Oncol. 2011;123:453-4.
    PubMed     Text format     Related articles   
    
    
    
21. HIGASHI M , Kajiyama H, Shibata K, Mizuno M, et al
    Survival impact of capsule rupture in stage I clear cell carcinoma of the ovary in comparison with other histological types.
    Gynecol Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
22. SHIH KK , Garg K, Soslow RA, Chi DS, et al
    Accuracy of frozen section diagnosis of ovarian borderline tumor.
    Gynecol Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
23. PARK JY , Kim DY, Kim JH, Kim YM, et al
    Micropapillary pattern in serous borderline ovarian tumors: Does it matter?
    Gynecol Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
24. VAY A , Kumar S, Seward S, Semaan A, et al
    Therapy-related myeloid leukemia after treatment for epithelial ovarian carcinoma: An epidemiological analysis.
    Gynecol Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    

    
    J Clin Oncol

25. KONSTANTINOPOULOS PA , Cannistra SA
    Comparing Poly (ADP-Ribose) Polymerase Inhibitors With Standard Chemotherapy in BRCA-Mutated, Recurrent Ovarian Cancer: Lessons Learned From a Negative Trial.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles   
    
    
    
26. KAYE SB , Lubinski J, Matulonis U, Ang JE, et al
    Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    

    
    Oncol Rep

27. BRUN JL , Cortez A, Lesieur B, Uzan S, et al
    Expression of MMP-2, -7, -9, MT1-MMP and TIMP-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer.
    Oncol Rep. 2011 Dec 22. doi: 10.3892/or.2011.1608.
    PubMed     Text format     Related articles    Abstract available
    
    
    
28. SHENG XJ , Zhou YQ, Song QY, Zhou DM, et al
    Loss of breast cancer metastasis suppressor 1 promotes ovarian cancer cell metastasis by increasing chemokine receptor 4 expression.
    Oncol Rep. 2011 Dec 19. doi: 10.3892/or.2011.1596.
    PubMed     Text format     Related articles    Abstract available
    
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: